Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.008x

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Hubei Biocause Pharmaceutical for the company's overall valuation and market capitalisation.

Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency. Explore earnings quality score of Hubei Biocause Pharmaceutical to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Metals X Ltd AU:MLX	0.134x
Chengdu Gas Group Co Ltd SHG:603053	-0.008x
Tennant Company NYSE:TNC	0.009x
Avanti Feeds Limited NSE:AVANTIFEED	0.257x
HNA Technology Co Ltd A SHG:600751	0.011x
Suburban Propane Partners LP NYSE:SPH	0.196x
TRUSTPILOT GROUP LS -01 F:6VZ	N/A
Xiamen King Long Motor Group Co Ltd SHG:600686	-0.128x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. View Hubei Biocause Pharmaceutical share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	CN¥33.63 Billion ≈ $4.92 Billion	CN¥9.53 Billion ≈ $1.40 Billion	0.283x	+30.37%
2022-12-31	CN¥34.60 Billion ≈ $5.06 Billion	CN¥7.52 Billion ≈ $1.10 Billion	0.217x	+95.29%
2021-12-31	CN¥37.47 Billion ≈ $5.48 Billion	CN¥4.17 Billion ≈ $610.58 Million	0.111x	-82.02%
2020-12-31	CN¥34.59 Billion ≈ $5.06 Billion	CN¥21.42 Billion ≈ $3.13 Billion	0.619x	-25.61%
2019-12-31	CN¥34.35 Billion ≈ $5.03 Billion	CN¥28.60 Billion ≈ $4.19 Billion	0.833x	+44.56%
2018-12-31	CN¥26.01 Billion ≈ $3.81 Billion	CN¥14.98 Billion ≈ $2.19 Billion	0.576x	+3463.41%
2017-12-31	CN¥26.70 Billion ≈ $3.91 Billion	CN¥431.58 Million ≈ $63.15 Million	0.016x	+114.07%
2016-12-31	CN¥20.40 Billion ≈ $2.98 Billion	CN¥-2.34 Billion ≈ $-342.76 Million	-0.115x	-338.31%
2015-12-31	CN¥1.78 Billion ≈ $261.01 Million	CN¥-46.73 Million ≈ $-6.84 Million	-0.026x	-128.83%
2013-12-31	CN¥1.44 Billion ≈ $210.17 Million	CN¥130.53 Million ≈ $19.10 Million	0.091x	+48.97%
2012-12-31	CN¥1.54 Billion ≈ $224.96 Million	CN¥93.79 Million ≈ $13.72 Million	0.061x	+28.87%
2011-12-31	CN¥1.41 Billion ≈ $206.93 Million	CN¥66.95 Million ≈ $9.80 Million	0.047x	-66.23%
2010-12-31	CN¥1.60 Billion ≈ $234.43 Million	CN¥224.58 Million ≈ $32.86 Million	0.140x	+2.40%
2007-12-31	CN¥866.03 Million ≈ $126.73 Million	CN¥118.56 Million ≈ $17.35 Million	0.137x	-22.71%
2006-12-31	CN¥723.71 Million ≈ $105.90 Million	CN¥128.19 Million ≈ $18.76 Million	0.177x	+166.20%
2005-12-31	CN¥731.23 Million ≈ $107.00 Million	CN¥48.66 Million ≈ $7.12 Million	0.067x	-14.08%
2004-12-31	CN¥723.91 Million ≈ $105.93 Million	CN¥56.07 Million ≈ $8.20 Million	0.077x	+58.41%
2001-12-31	CN¥762.99 Million ≈ $111.65 Million	CN¥37.30 Million ≈ $5.46 Million	0.049x	--

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8359 Global

#1946 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.58 - CN¥1.58

All Time High

CN¥10.45